Ingersoll Rand (IR) Q4 FY25 earnings call: guidance and Q&A

What end market trajectory is embedded in the guidance, particularly for short-cycle businesses, and what internal leading indicators are you observing?

The guidance assumes current stable sequential trajectory without embedding market recovery. Life Sciences is improving, general industrial is stabilizing, and long-cycle funnel remains healthy. PMI serves as a good gauge for short-cycle, with a recent uptick in U.S. PMI noted, but it's too early to call a meaningful inflection.

“We're not embedding any market recovery here, and very stable sequentially here from what we are seeing today.”

asked by Michael Halloran · answered by Vicente Reynal

Is the guidance based on roughly 1% organic revenue growth evenly through the year, and is Q1 EPS growth expected to be around mid-single digits?

Q1 organic revenue is expected to be flat to slightly down, with comparable low single-digit growth for Q2, Q3, and Q4. EPS growth is expected to be relatively even on a quarterly basis, with mid-single-digit growth in both the first and second halves.

“we expect Q1 organic to be, I'd say, roughly flat to maybe very slightly down. But then as we move through the balance of the year, we expect, I would call it, comparable low single-digit growth -- organic growth for Q2, Q3 and Q4.”

asked by Julian Mitchell · answered by Vikram Kini

How should we think about full-year EBITDA margins being flattish, particularly regarding price/cost headwinds in H1 and ITS margins?

Full-year EBITDA margins are expected to be flattish. H1 will see margin headwinds from annualizing tariffs, leading to price/cost neutrality. H2 is expected to show margin expansion due to in-year pricing actions and productivity. ITS margins are expected to be flattish for the full year due to tariffs and investments, while PST margins are expected to expand significantly.

“price/cost expected to be a bit more constrained in the first half of the year given the timing of the tariff impact. However, we do expect to be price/cost neutral in the first half. And then we expect to see that margin expansion take hold in the second half.”

asked by Julian Mitchell · answered by Vikram Kini

Can you elaborate on the composition of the M&A pipeline (bolt-on vs. larger deals) and the drivers behind the recurring revenue growth?

The M&A funnel is strong, primarily bolt-on, but includes a couple of larger deals (around $1 billion) under cultivation. Recurring revenue grew to over $450 million in 2025 with a $1.1 billion backlog, driven by expanding into new regions and integrating recurring revenue across various technologies.

“the current pipeline is bolt-on in nature today. But we're definitely seeing a lot of good activity and particularly on what I just referred to. I mean this -- our cultivation process continues to remain very strong, and we're seeing better movement here too as well.”

asked by Joe O'Dea · answered by Vicente Reynal

Given mid-teens organic order growth in Life Sciences, what caused the implied decline in other PST business units?

Life Sciences and Precision Technology (60% of PST) performed well. The offset came from the Aerospace and Defense business, which was down due to order timing but is generally expected to move sideways from 2025 to 2026.

“The last piece is basically the Aerospace and Defense business, which is down due to order timing. Nothing unexpected as the business is generally moving sideways from 2025 to 2026.”

asked by Nigel Coe · answered by Vicente Reynal

Does the EBITDA guidance embed any cost actions or productivity gains, given the limited volume growth assumption?

The guidance includes requisite productivity and cost actions. This includes savings from proactive restructuring in H2 2025, normal course productivity (direct material, I2V) with a second-half weighting, and targeted pricing actions throughout the year. These actions offset tariff headwinds, commercial reinvestments, and increased corporate costs.

“The driver of that or the kind of the offset tends to come from some of those cost actions. So first and foremost, you have seen in our financials here that we have taken some proactive restructuring actions in the back half of 2025. Those will continue to materialize into savings into 2026.”

asked by Nathan Jones · answered by Vikram Kini

Was the Q4 organic growth pickup driven more by short-cycle momentum or long-cycle backlog conversion, and could backlog release be a tailwind into H1 2026?

Q4 performance had components from both short-cycle (base business, aftermarket, recurring revenue) and long-cycle projects, as Q4 is typically a heavier shipment quarter for long-cycle. The full-year book-to-bill slightly over 1x indicates some backlog build, providing increased visibility and execution potential into 2026.

“Q4 performance, I saw -- I would say, had a requisite, I'd say, a component of both, what I would say, the base business or short cycle inclusive of aftermarket and recurring revenue as well as the long cycle.”

asked by Christopher Snyder · answered by Vikram Kini

Why were ITS organic orders in EMEA down mid-single digits in Q4, given generally more constructive sentiment from Europe?

The decline was due to project timing and nothing to read into, as the EMEA business still achieved positive low single-digit organic order growth for the full year. Some Mediterranean countries are growing faster than Central European ones like Germany.

“No, just -- I mean nothing to read into it. I mean just project timing, basically, and that was basically -- I mean -- but again, we continue to be really encouraged.”

asked by David Raso · answered by Vicente Reynal